BRAF V600	Melanoma	BRAF V600	Melanoma	pembrolizumab + NLG8189 Sensitive: C2 – Inclusion Criteria pembrolizumab + NLG8189 Sensitive : C2	pembrolizumab + NLG8189 Sensitive: C2 – Inclusion Criteria pembrolizumab + NLG8189 Sensitive : C2
BRAF V600	Melanoma	BRAF V600	Melanoma	nivolumab + NLG8189 Sensitive: C2 – Inclusion Criteria nivolumab + NLG8189 Sensitive : C2	nivolumab + NLG8189 Sensitive: C2 – Inclusion Criteria nivolumab + NLG8189 Sensitive : C2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	NLG8189 Resistant: C3 – Early Trials NLG8189 Resistant : C3	NLG8189 Resistant: C3 – Early Trials NLG8189 Resistant : C3
PD-L1 expression	Melanoma	PD-L1 expression	Melanoma	pembrolizumab + NLG8189 Sensitive: C3 – Early Trials pembrolizumab + NLG8189 Sensitive : C3	pembrolizumab + NLG8189 Sensitive: C3 – Early Trials pembrolizumab + NLG8189 Sensitive : C3

indoximod (NLG8189)

Associations
(4)